SCHEMBL4432790

SCHEMBL4432790

CC(C(=O)N(C)C)c1ccc(F)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.46
CES1 P23141 3/20 0.46
HTT P42858 1/20 0.46
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
AVPR2 P30518 1/20 0.42
OXTR P30559 1/20 0.42
CYP2C19 P33261 1/20 0.42
AVPR1A P37288 1/20 0.42
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RECQL P46063 1/20 0.39
NPY2R P49146 1/20 0.39
PTGS1 P23219 5/20 0.38
PTGS2 P35354 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31117279 0.80 PTGS1 (0.54) CES2CES1CYP1A2CYP2C9CYP2C19
SCHEMBL19182930 0.80 PTGS1 (0.54) CES2CES1CYP1A2CYP2C9CYP2C19
SCHEMBL19182931 0.80 PTGS1 (0.54) CES2CES1CYP1A2CYP2C9CYP2C19
SCHEMBL19200282 0.79 CES2 (0.49) CES2CES1HTTOXTRRECQL
SCHEMBL31117167 0.76 CES2 (0.46) CES2CES1RECQLPTGS1PTGS2
SCHEMBL31560789 0.76 CES2 (0.46) CES2CES1RECQLPTGS1PTGS2
SCHEMBL4425970 0.74 KMT2A (0.44) HTTKMT2A
SCHEMBL4429225 0.74 CES2 (0.47) CES2CES1KMT2AMEN1HPGD
SCHEMBL9412496 0.73 HIF1A (0.49) CES2CES1RECQLPTGS1PTGS2
SCHEMBL11460560 0.73 AKR1C3 (0.43) CYP1A2CYP2C9MAPTL3MBTL1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
EP-2033953-A1 Vanilloid receptor modulators Glaxo Group Limited (GB) 2009-03-11 EP disclosed
US-20060142333-A1 Vanilloid receptor modulators MACDONALD GREGOR J 2006-06-29 US disclosed
EP-1480954-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2004-12-01 EP disclosed
WO-2003068749-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142333-A1 Vanilloid receptor modulators TRPV1, NPSR1, TRPV3 CES2 1914/4885CES1 1861/4885HTT 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.